Sean Lee

Justin Zelin

Leland Gershell

Trevor Allred

- CASI Pharmaceuticals reported **Q2 2025 revenues of $4.2 million** and a **net loss of $13.4 million**.  **[1962738_0001104659-25-085718_tm2524634d1_ex99-1.htm:0]** **[1962738_0001104659-25-085718_tm2524634d1_ex99-1.htm:1]**  Cash and cash equivalents stood at **$6.7 million** as of June 30, 2025.  **[1962738_0001104659-25-085718_tm2524634d1_ex99-1.htm:1]** **[1962738_0001104659-25-085718_tm2524634d1_ex99-1.htm:6]** 
- The company entered into a definitive agreement to **divest its 100% equity interests in two China subsidiaries and certain product licensing rights** for an aggregate purchase price of **$20.0 million**, including assumption of up to $20.0 million of indebtedness.  **[1962738_0001104659-25-085718_tm2524634d1_ex99-1.htm:0]** 
- CASI received **FDA clearance for its IND application for CID-103** in renal allograft antibody-mediated rejection (AMR) and plans to initiate a Phase 1 study in the third quarter of 2025.  **[1962738_0001104659-25-085718_tm2524634d1_ex99-1.htm:0]** **[1962738_0001104659-25-085718_tm2524634d1_ex99-1.htm:1]**

CASI Pharmaceuticals Announces Q2 2025 Results and Strategic Divestiture

- **CASI Pharmaceuticals, Inc.** announced that its **Import Drug Registration License for FOLOTYN® in China expired on August 25, 2025**.  **[1962738_0001104659-25-084032_tm2524476d1_6k.htm:1]** 
- The **Chinese Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) did not grant the company's renewal application** for the license.  **[1962738_0001104659-25-084032_tm2524476d1_6k.htm:1]** 
- As a direct consequence, CASI Pharmaceuticals **will immediately cease the sale of FOLOTYN® in China**.  **[1962738_0001104659-25-084032_tm2524476d1_6k.htm:1]** 
- The company may, however, **continue FOLOTYN® clinical trial activities in China**.  **[1962738_0001104659-25-084032_tm2524476d1_6k.htm:1]**

CASI Pharmaceuticals (CASI)